Literature DB >> 29616127

Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: Case report and review of the literature.

Arsela Prelaj1, Sara Elena Rebuzzi2, Giovanni Caffarena3, Julio Rodrigo Giròn Berrìos1, Silvia Pecorari1, Carmela Fusto1, Alessandro Caporlingua4, Federico Caporlingua4, Annamaria Di Palma5, Fabio Massimo Magliocca6, Maurizio Salvati7, Silverio Tomao8, Vincenzo Bianco1.   

Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive malignant glioma that is treated with first-line therapy, using surgical resection followed by local radiotherapy and concomitant/adjuvant temozolomide (TMZ) treatment. GBM is characterised by a high local recurrence rate and a low response to therapy. Primitive neuroectodermal tumour (PNET) of the brain revealed a low local recurrence rate; however, it also exhibited a high risk of cerebrospinal fluid (CSF) dissemination. PNET is treated with surgery followed by craniospinal irradiation (CSI) and platinum-based chemotherapy in order to prevent CSF dissemination. GBM with PNET-like components (GBM/PNET) is an emerging variant of GBM, characterised by a PNET-like clinical behaviour with an increased risk of CSF dissemination; it also may benefit from platinum-based chemotherapy upfront or following failure of GBM therapy. The results presented regarding the management of GBM/PNET are based on case reports or case series, so a standard therapeutic approach for GBM/PNET is not defined, constituing a challenging diagnostic and therapeutic dilemma. In this report, a case of a recurrent GBM/PNET treated with surgical resection and radiochemotherapy as Stupp protocol, and successive platinum-based chemotherapy due to the development of leptomeningeal dissemintation and an extracranial metastasis, is discussed. A review of the main papers regarding this rare GBM variant and its therapeutic approach are also reported. In conclusion, GBM/PNET should be treated with a multimodal approach including surgery, chemoradiotherapy, and/or the early introduction of CSI and platinum-based chemotherapy upfront or at recurrence.

Entities:  

Keywords:  craniospinal irradiation; glioblastoma multiforme; platinum-based chemotherapy; primitive neuroectodermal tumor; treatment

Year:  2018        PMID: 29616127      PMCID: PMC5876436          DOI: 10.3892/ol.2018.8102

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  Supratentorial primitive neuroectodermal tumors of the central nervous system in adults: molecular and histopathologic analysis of 12 cases.

Authors:  Marco Gessi; Prashanth Setty; Michele Bisceglia; Anja zur Muehlen; Libero Lauriola; Andreas Waha; Felice Giangaspero; Torsten Pietsch
Journal:  Am J Surg Pathol       Date:  2011-04       Impact factor: 6.394

2.  New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases.

Authors:  Pascale Varlet; Deepa Soni; Catherine Miquel; François-Xavier Roux; Jean-François Meder; Herve Chneiweiss; Catherine Daumas-Duport
Journal:  Neurosurgery       Date:  2004-12       Impact factor: 4.654

Review 3.  Glioblastoma: Overview of Disease and Treatment.

Authors:  Mary Elizabeth Davis
Journal:  Clin J Oncol Nurs       Date:  2016-10-01       Impact factor: 1.027

4.  Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.

Authors:  Arie Perry; C Ryan Miller; Meena Gujrati; Bernd W Scheithauer; Sandro Casavilca Zambrano; Sarah C Jost; Ravi Raghavan; Jiang Qian; Elizabeth J Cochran; Jason T Huse; Eric C Holland; Peter C Burger; Marc K Rosenblum
Journal:  Brain Pathol       Date:  2008-04-29       Impact factor: 6.508

5.  Glioblastoma with primitive neuroectodermal tumor-like features: case report.

Authors:  Nilüfer Onak Kandemir; Burak Bahadir; Sanser Gül; Nimet Karadayi; Sükrü Oğuz Ozdamar
Journal:  Turk Neurosurg       Date:  2009-07       Impact factor: 1.003

6.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

7.  The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells.

Authors:  Zeyou Wang; Qin Guo; Rong Wang; Gang Xu; Peiyao Li; Yingnan Sun; Xiaoling She; Qiang Liu; Qiong Chen; Zhibin Yu; Changhong Liu; Jing Xiong; Guiyuan Li; Minghua Wu
Journal:  J Hematol Oncol       Date:  2016-11-25       Impact factor: 17.388

Review 8.  Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.

Authors:  Song Xue; Man Hu; Veena Iyer; Jinming Yu
Journal:  J Hematol Oncol       Date:  2017-04-07       Impact factor: 17.388

Review 9.  Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma.

Authors:  Wan-Ling Ho; Wen-Ming Hsu; Min-Chuan Huang; Kenji Kadomatsu; Akira Nakagawara
Journal:  J Hematol Oncol       Date:  2016-09-29       Impact factor: 17.388

Review 10.  Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.

Authors:  Wojciech Szopa; Thomas A Burley; Gabriela Kramer-Marek; Wojciech Kaspera
Journal:  Biomed Res Int       Date:  2017-02-20       Impact factor: 3.246

View more
  7 in total

Review 1.  Leptomeningeal Spread in Glioblastoma: Diagnostic and Therapeutic Challenges.

Authors:  Cristina Birzu; Suzanne Tran; Franck Bielle; Mehdi Touat; Karima Mokhtari; Nadia Younan; Dimitri Psimaras; Khe Hoang-Xuan; Marc Sanson; Jean-Yves Delattre; Ahmed Idbaih
Journal:  Oncologist       Date:  2020-08-31

2.  Glioblastoma with primitive neuronal component: A case report and considerations of fluorescence-guided surgery.

Authors:  Juan Francisco Sánchez-Ortega; Jesús Aguas-Valiente; Patricia Sota-Ochoa; Juan Calatayud-Pérez
Journal:  Surg Neurol Int       Date:  2020-07-04

3.  ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma.

Authors:  Xiaonan Xi; Ning Liu; Qianqian Wang; Yahui Chu; Zheng Yin; Yahui Ding; Yaxin Lu
Journal:  Cell Death Dis       Date:  2019-10-07       Impact factor: 8.469

4.  A Prospective Clinical Study on MGMT Protein Expression and the Effect of Gene Promoter Methylation on Sensitivity to Chemotherapeutics in Spinal Glioma.

Authors:  Peng Sun; Duo-Jiao Fan; Tao Fan; Xin Li; Xue-Ling Qi; Xin-Gang Zhao; Qi-Fei Gai
Journal:  J Inflamm Res       Date:  2021-09-18

5.  A Rare Manifestation of a Presumed Non-Osteophilic Brain Neoplasm: Extensive Axial Skeletal Metastases From Glioblastoma With Primitive Neuronal Components.

Authors:  Tianhua Rong; Wanjing Zou; Xiaoguang Qiu; Wei Cui; Duo Zhang; Bingxuan Wu; Zhuang Kang; Wenbin Li; Baoge Liu
Journal:  Front Oncol       Date:  2021-11-02       Impact factor: 6.244

6.  Do Glioblastomas with Syndromic Association Have Better Prognosis? A Case of Supratentorial Glioblastoma with Embryonal Tumor Differentiation in a Child with Multiple Enchondromatosis.

Authors:  Siddharth Vankipuram; Sushant Sahoo; Shalini Bhalla; Chittij Srivastava
Journal:  J Pediatr Neurosci       Date:  2019-12-03

7.  Glioblastoma multiforme: a multi-omics analysis of driver genes and tumour heterogeneity.

Authors:  Gabriel Emilio Herrera-Oropeza; Carla Angulo-Rojo; Santos Alberto Gástelum-López; Alfredo Varela-Echavarría; Maribel Hernández-Rosales; Katia Aviña-Padilla
Journal:  Interface Focus       Date:  2021-06-11       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.